Discussion {#onco12294-sec-0005}
==========

The management of localized rectal cancer has evolved into a multidisciplinary effort that requires medical, radiation, and surgical oncologists to elucidate an optimal treatment plan. Combination of chemo and radiation therapy is currently the standard of care for patients with localized rectal cancer. This combination has been associated with a pCR rate of 15%--20%, SSS rate of 39%--44%, and SD rate of 40%--80%. Grade 3 or higher radiation dermatitis at 43%--78% and proctitis at 2%--39% have been previously reported.

At the inception of this trial in 2005, 5‐fluorouracil (5‐FU) and oxaliplatin in combination with radiation therapy (RT) were standard of care in the neoadjuvant setting for localized rectal cancer. Over the last few years, the utility of adding oxaliplatin to 5‐FU/capecitabine has been called into question and multiple well‐designed prospective trials have shown that 5‐FU or capecitabine (oral prodrug for 5‐FU) alone with RT is as efficacious with improved tolerability.

Based on robust preclinical evidence of increased COX‐2 expression in rectal cancer and multiple preclinical studies showing improved radiation response, decreased microvessel density, inhibition of angiogenesis and metastasis with COX‐2 inhibition, we designed this trial to potentially improve upon pCR results and assess tolerability of the combination of celecoxib with standard of care chemotherapy and RT. Our trial noted a pCR rate of 31%, SD rate of 75%, and SSS rate of 56%, and very good treatment tolerance as evidenced by absence of grade 3 dermatitis and lower incidence of grade 3 proctitis (3%) as compared with historical data.

Another phase II trial of 35 patients treated rectal cancer patients with 5‐FU plus celecoxib 400 MG BID versus 5‐FU plus placebo in the neoadjuvant setting. This trial showed an improved pCR rate in the celecoxib group, although results were not statistically significant (pCR 39% vs. 29%); and better response defined as good regression + pCR (61% vs. 35%; *p* = .13 for both). Authors concluded a trend toward better response and improvement in treatment‐related pain in the experimental arm.

From our encouraging response data and toxicity results, along with other recent trials reporting futility of adding oxaliplatin, there exists a potential to use only 5‐FU/capecitabine in combination with celecoxib in future trials. This combination holds potential in improving toxicity further when compared with 5‐FU and RT while preserving or possibly improving response rates.

Reported concerns of COX‐2 inhibition such as peptic ulcer disease and ischemic cardiovascular diseases occur with longer‐term administration of these drugs, and in our study, there were no such side effects observed.

The limitations of this study were slow accrual rate over 7 years, addition of oxaliplatin, which has since shown to be inactive in this setting, relatively small sample size, and lack of a comparator arm.

Trial Information {#onco12294-sec-0006}
=================

**Disease**Colorectal cancer**Stage of Disease/Treatment**Neo‐adjuvant**Prior Therapy**None**Type of Study ‐ 1**Phase II**Type of Study ‐ 2**Single arm**Primary Endpoint**pCR**Secondary Endpoint**Toxicity**Secondary Endpoint**SD**Secondary Endpoint**Incidence of SSS**Secondary Endpoint**Progression‐free survival**Secondary Endpoint**OS**Secondary Endpoint**Pelvic recurrence**Additional Details of Endpoints or Study Design** This study used a Simon two‐stage optimum design so that the study could be terminated early for futility. In stage I of this design, we enrolled 19 patients, and if 3 or fewer achieved pCR (≤15% recurrence rate (RR)), with a probability of 0.68, the study would be terminated. If 4 or more patients achieved pCR, the study would enroll an additional 36 patients, for a total of 55, to achieve an 80% power to detect a pCR of ≥30% at one‐sided 5% level of significance. If 12 or fewer patients achieved pCR over the two stages, futility would be declared.The study was terminated without completing accrual; 38 patients were enrolled, of whom 32 were included in final analysis. **Investigator\'s Analysis**Active and should be pursued further

Drug Information for Phase II Study {#onco12294-sec-0007}
===================================

Drug 1 Generic/Working nameOxaliplatinTrade nameEloxatinCompany namePfizerDrug typeChemotherapyDrug classPlatinum compoundDose50 milligrams (mg) per squared meter (m^2^)RouteIVSchedule of administrationWeeklyDrug 2 Generic/Working nameCapecitabineTrade nameXelodaCompany nameGenentechDrug typeOtherDrug classAntimetaboliteDose850 mg/m^2^Routep.o.Schedule of administrationb.i.d. Monday through FridayDrug 3 Generic/Working nameCelecoxibTrade nameCelebrexCompany namePfizerDrug typeCOX‐2 inhibitorDrug classAnti‐inflammatoryDose200 mg per flat doseRoutep.o.Schedule of administrationb.i.d. daily without interruption

Patient Characteristics for Phase II Study {#onco12294-sec-0011}
==========================================

Number of Patients, Male18Number of Patients, Female14StageStage IIa: 8Stage IIb: 22Stage III: 2AgeMedian (range): 52.7 years (±12.7)Number of Prior Systemic TherapiesMedian (range): 0Performance Status: ECOGPatients were required to have ECOG performance status 0--2

 {#onco12294-sec-1011}

**Patient Characteristics*n*Ethnicity** **Hispanic**17**White**12**Asian**1**Native American**1**Not reported**1**TNM staging** **T3**30**T4**2**N0**7**N1**16**N2**8**Mean CEA levels**7.4 ± 11.4**Mean BMI mg/m^2^**27.1 ± 5.2Abbreviations: BMI, basal metabolic index; CEA, carcino embryonic antigen; TNM, tumor, node, metastasis. 

Primary Assessment Method for Phase II Study {#onco12294-sec-0012}
============================================

TitleTotal Patient PopulationNumber of Patients Screened80Number of Patients Enrolled38Number of Patients Evaluable for Toxicity32Number of Patients Evaluated for Efficacy32Evaluation MethodpCR on surgeryResponse Assessment CR*n* = 10 (31%)

Phase II Study Adverse Events {#onco12294-sec-0013}
=============================

imageJohn Wiley & Sons, Ltd.[^1]

Assessment, Analysis, and Discussion {#onco12294-sec-0015}
====================================

CompletionStudy terminated before completionTerminated ReasonDid not fully accrueInvestigator\'s AssessmentActive and should be pursued further

 {#onco12294-sec-0016}

Approximately 135,430 new cases of colorectal cancer in the U.S. are estimated for 2017 (approximately 95,520 colon and 39,910 rectal cancers), accounting for 8% of all new cancer cases following breast, lung, and prostate cancers \[[1](#onco12294-bib-0001){ref-type="ref"}\]. The 5‐year probability of death from loco‐regional rectal cancer is 44%, and local recurrence rate can be up to 40% \[[2](#onco12294-bib-0002){ref-type="ref"}\], \[[3](#onco12294-bib-0003){ref-type="ref"}\]. Therefore, it is important to explore treatment strategies that can affect survival and improve treatment toxicity profile for rectal cancer.

The landmark German Rectal Cancer study group CAO/ARO/AIO‐94 identified improved local control with preoperative versus postoperative chemoradiation \[[4](#onco12294-bib-0004){ref-type="ref"}\]. Updated results from the same study showed the degree of tumor regression and the rate of pathologic complete response (pCR) were associated with improved metastasis‐free and disease‐free survival as well as a lower local recurrence rate. Therefore, pCR is considered an acceptable endpoint for phase II studies.

This study was a nonrandomized, single‐center, single‐arm, phase II clinical trial that evaluated the efficacy of adding celecoxib to standard concurrent neoadjuvant chemoradiation for surgically resectable rectal cancer patients. Enrollment of patients started in 2005, with accrual completing in 2012. The statistical design allowed enrollment of patients after the first stage of the study; however, further accrual was low and the study was closed without reaching the expected 55 patients. A data cutoff for survival analysis was done in February 2015. A total of 38 patients were enrolled; 2 withdrew consent before starting therapy, 3 became ineligible prior to starting therapy, and 1 observation had missing data for analysis. There were 32 patients available for efficacy and toxicity analysis.

The management of rectal cancer has evolved into a multidisciplinary effort that requires medical, radiation, and surgical oncologists to elucidate an optimal treatment plan. The standard of care currently is the combination of chemotherapy and radiation. Chemoradiation has been associated with a pCR rate of 15%--20%, sphincter‐sparing surgery (SSS) rate of 39%--44%, surgical downstaging (SD) rate of 40%--80%, incidence of grade 3 or more radiation dermatitis of 43%--78%, and an incidence of radiation proctitis of 2%--39% \[[5](#onco12294-bib-0005){ref-type="ref"}\], \[[6](#onco12294-bib-0006){ref-type="ref"}\], \[[7](#onco12294-bib-0007){ref-type="ref"}\], \[[8](#onco12294-bib-0008){ref-type="ref"}\], \[[9](#onco12294-bib-0009){ref-type="ref"}\], \[[10](#onco12294-bib-0010){ref-type="ref"}\]. To improve upon these results, we decided to add a cyclooxygenase‐2 (COX‐2) inhibitor (celecoxib) to the then‐established treatment regimen of 5‐FU, oxaliplatin, and radiation. The rationale of adding celecoxib was based on robust preclinical evidence of increased COX‐2 expression in rectal cancer and multiple preclinical studies showing improved radiation response, decreased tumor microvessel density, and inhibition of metastasis and angiogenesis with COX‐2 inhibition \[[11](#onco12294-bib-0011){ref-type="ref"}\], \[[12](#onco12294-bib-0012){ref-type="ref"}\], \[[13](#onco12294-bib-0013){ref-type="ref"}\]. Our trial noted a pCR rate of 31%, SD rate of 75%, and SSS rate of 56%, and the treatment was well tolerated as evidenced by absence of grade 3 dermatitis and low incidence of grade 3 proctitis (3%) (Table [2](#onco12294-tbl-0002){ref-type="table"}).

When this protocol was initiated in 2005, the addition of oxaliplatin to fluoropyrimidines and radiation therapy seemed promising \[[14](#onco12294-bib-0014){ref-type="ref"}\], \[[15](#onco12294-bib-0015){ref-type="ref"}\]. However, more recent large prospective trials asserted that the addition of oxaliplatin was actually associated with increased toxicity without significant improvement in pCR when compared with capecitabine alone \[[16](#onco12294-bib-0016){ref-type="ref"}\], \[[17](#onco12294-bib-0017){ref-type="ref"}\], \[[18](#onco12294-bib-0018){ref-type="ref"}\].

The addition of celecoxib may have indeed improved pCR and resulted in a more favorable toxicity profile. Benefit from celecoxib may have been related to an enhanced radiation‐induced apoptosis or direct inhibition of tumor neovascularization when a COX‐2 inhibitor was added. Another phase II trial of 5‐FU with celecoxib 400 MG BID versus placebo in the neoadjuvant treatment of rectal cancer showed an improved pCR rate in the celecoxib group, but was not statistically significant (pCR 39% vs. 29%); and better response (good regression + pCR: 61% vs. 35%; *p* = .13 for both) \[[19](#onco12294-bib-0019){ref-type="ref"}\].

Secondary endpoints of this trial were to assess the rates of SSS and SD. We observed SSS rate of 56% and SD rate of 75%, as compared with the reported rates of SD at 54% (ranging from 40% to 80%) and SSS at 39%--44% \[[7](#onco12294-bib-0007){ref-type="ref"}\], \[[8](#onco12294-bib-0008){ref-type="ref"}\], \[[17](#onco12294-bib-0017){ref-type="ref"}\]. Disease‐free survival and overall survival rates at 3 years were 84% (95% confidence interval \[CI\]: 65%--93%) and 94% (95% CI: 77%--98%), respectively (Fig. [1](#onco12294-fig-0001){ref-type="fig"}).

![Survival analysis. Kaplan‐Meier survival curve for the entire group (black line) and the upper and lower 95% confidence intervals (dotted lines).\
Abbreviations: DFS, disease‐free survival; OS, overall survival.](onco12294-fig-0001){#onco12294-fig-0001}

Issues concerning toxicity of COX‐2 inhibitors such as peptic ulcer disease and ischaemic heart disease have been observed only with long‐term administration \[[20](#onco12294-bib-0020){ref-type="ref"}\], \[[21](#onco12294-bib-0021){ref-type="ref"}\]. There were no reported cases of either of these two complications in our study. The good tolerability was likely due to the relatively short period and low dose of the COX‐2 inhibitor. Incidence of proctitis and dermatitis was 37% and 13%, respectively, with only one patient experiencing grade 3 proctitis; historically, grade 3 or 4 proctitis has been reported at 43%--78% and dermatitis at 2%--39% \[[10](#onco12294-bib-0010){ref-type="ref"}\]. Also, as suggested by Zhang et al., it is possible that improved tolerance of capecitabine among our patients was possibly related to the use of celecoxib \[[22](#onco12294-bib-0022){ref-type="ref"}\].

We also performed COX‐2 expression analysis (Figs. [2](#onco12294-fig-0002){ref-type="fig"}, [3](#onco12294-fig-0003){ref-type="fig"}) in a subset of patients (18/32). However, none of the associations tested, namely pCR, SD, SSS, and dermatitis and proctitis incidence, were related to the degree of tumor expression of COX‐2 (Table [1](#onco12294-tbl-0001){ref-type="table"}). However, it was remarkable that pretreatment COX‐2 expression remained 80% unchanged in pre‐ versus postradiation among nonresponders. Prior studies have suggested an increase in COX‐2 expression after radiation, whereas others suggest less COX‐2 expression with celecoxib \[[23](#onco12294-bib-0023){ref-type="ref"}\], \[[24](#onco12294-bib-0024){ref-type="ref"}\]. In our trial, celecoxib did not seem to affect COX‐2 expression but the improved results may be related to COX‐2 enzyme function and downstream signaling.

![Cyclooxygenase‐2 positive on immunohistochemistry.](onco12294-fig-0002){#onco12294-fig-0002}

![Cyclooxygenase‐2 negative on immunohistochemistry.](onco12294-fig-0003){#onco12294-fig-0003}

The limitations of this study were slow accrual rate over 7 years, where most of the patients came from a single center, with a 40% enrollment/screen ratio in a less populous state. The sample size is limited to 32 patients and a larger randomized study would be needed to better determine the effectiveness of this combination. Future studies should focus on combination of 5‐FU/capecitabine and celecoxib versus 5‐FU plus placebo in combination RT in neoadjuvant setting. Cyclooxygenase‐2 staining has not been standardized and variability in reproducibility may be present; although we were only able to test COX‐2 expression in 18 patients, we did not find it to be a predictable biomarker.

Most of the recent improvements in rectal cancer management have been in the metastatic setting, especially with the advent of immunotherapy in microsatellite instability‐high patients. This trial showed an inexpensive drug such as celecoxib was well tolerated and improved clinical outcomes. We believe combination of 5‐FU and celcoxib holds promise in treatment of localized rectal cancer. Our main limitation was slow accrual; a multi‐institutional, randomized study may help mitigate this limitation, and we would like to pursue this in the future.

Tables {#onco12294-sec-1917}
======

###### COX‐2 immunohistochemistry status at diagnosis

![](onco12294-tbl-0002){#nlm-graphic-15}

*p* value obtained from the Fisher\'s exact test.

Abbreviations: pCR, pathologic complete response; SD, surgical downstaging; SSS, sphincter‐sparing surgery.

###### Adverse events by grade in evaluable patients

![](onco12294-tbl-0003){#nlm-graphic-17}

[ClinicalTrials.gov](http://ClinicalTrials.gov) Identifier: [NCT00250835](https://clinicaltrials.gov/ct2/show/NCT00250835)
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[Click here to access other published clinical trials](http://theoncologist.alphamedpress.org/cgi/collection/clinical-trial-results).
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